INNOVUS PHARMA INC COM USD0.001 (INNV)

0.26
OTC Markets
Prev Close 0.26
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.03 / 0.66
Exchange OTC Markets
Shares Outstanding 106.08B
Market Cap 27.37M
Div & Yield N.A. (N.A)

Latest News

Innovus Pharma Launches Zestra® Multi-Dose Form For Female Sexual Arousal In The U.S.

Innovus Pharma Launches Zestra® Multi-Dose Form For Female Sexual Arousal In The U.S.

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer...

Innovus Pharma Reports Record Quarterly Revenues For The Third Quarter Of 2016, Increasing 947% To $1.9 Million, And Record Nine Months Ended September 2016 Revenues, Increasing 463% To $3.1 Million

Innovus Pharma Reports Record Quarterly Revenues For The Third Quarter Of 2016, Increasing 947% To $1.9 Million, And Record Nine Months Ended September 2016 Revenues, Increasing 463% To $3.1 Million

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), today announced a 947% increase in third quarter of 2016 revenues to a record $1.

Innovus Pharma Signs Exclusive License And Distribution Agreement With Elis Pharmaceuticals For Zestra® In Lebanon

Innovus Pharma Signs Exclusive License And Distribution Agreement With Elis Pharmaceuticals For Zestra® In Lebanon

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV) announced today it has entered into its second exclusive license and distribution agreement with Elis Pharmaceuticals, Ltd.

Innovus Pharmaceuticals To Release Third Quarter 2016 Financial Results And Provide Corporate Update On Thursday, November 10, 2016

Innovus Pharmaceuticals To Release Third Quarter 2016 Financial Results And Provide Corporate Update On Thursday, November 10, 2016

Innovus Pharmaceuticals, Inc., ("Innovus Pharma") (OTCQB: INNV), today announced that the Company will release its third quarter 2016 financial results and provide a corporate update on Thursday, November 10, 2016, after...

Innovus Pharma Initiates Pre-Clinical And Clinical Program Evaluating The Safety And Efficacy Of Vesele® With Sildenafil (Viagra®)

Innovus Pharma Initiates Pre-Clinical And Clinical Program Evaluating The Safety And Efficacy Of Vesele® With Sildenafil (Viagra®)

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company delivering over-the-counter medicines and consumer care products for men's and...

Innovus Pharmaceuticals Licenses Urox® Formulation, A Clinically Proven Product For Overactive Bladder And Urinary Incontinence

Innovus Pharmaceuticals Licenses Urox® Formulation, A Clinically Proven Product For Overactive Bladder And Urinary Incontinence

Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") (OTCQB Venture Market:INNV) an emerging commercial stage pharmaceutical company delivering over-the-counter medicines and consumer care products for men's...

Innovus Pharma Announces The U.S. Launch Of Sensum+®, A Clinically Proven Product To Increase Penile Sensitivity, On Its Beyond Human Sales And Marketing Platform

Innovus Pharma Announces The U.S. Launch Of Sensum+®, A Clinically Proven Product To Increase Penile Sensitivity, On Its Beyond Human Sales And Marketing Platform

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer...

Innovus Pharma To Present At Rodman & Renshaw 18th Annual Global Investment Conference

Innovus Pharma To Present At Rodman & Renshaw 18th Annual Global Investment Conference

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer...

RecalMax™ Promotes Healthy Brain Function (Photo: Business Wire)

RecalMax™ Promotes Healthy Brain Function (Photo: Business Wire)

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer...

With Revenues Climbing, Innovus Pharma Adds Robert E. Hoffman As Its Chief Financial Officer

With Revenues Climbing, Innovus Pharma Adds Robert E. Hoffman As Its Chief Financial Officer

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer...

Innovus Pharma Announces The Approval Of The Product Licenses For Zestra®, Zestra Glide®, EjectDelay® And Sensum+® By The Indian FDA (Directorate General Of Health Services) Through Its Partner Khandelwal Laboratories

Innovus Pharma Announces The Approval Of The Product Licenses For Zestra®, Zestra Glide®, EjectDelay® And Sensum+® By The Indian FDA (Directorate General Of Health Services) Through Its Partner Khandelwal Laboratories

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage cash flow positive pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine...

Innovus Pharma Signs License Agreement With Sothema Laboratories For Zestra(R) And Zestra Glide(R) In The Middle East (Excluding Lebanon And Israel), North Africa And West Africa

Innovus Pharma Signs License Agreement With Sothema Laboratories For Zestra(R) And Zestra Glide(R) In The Middle East (Excluding Lebanon And Israel), North Africa And West Africa

Innovus Eligible to Receive Upfront and Up to $171.25 Million U.S. in Sales Milestone Payments Plus Transfer Price

Innovus Pharma Signs License Agreement With Orimed Pharma For Zestra(R), EjectDelay(TM), Sensum+(TM) And Zestra Glide(R) In Canada

Innovus Pharma Signs License Agreement With Orimed Pharma For Zestra(R), EjectDelay(TM), Sensum+(TM) And Zestra Glide(R) In Canada

Innovus Eligible to Receive Up to $94.5 Million CAD in Upfront and Sales Milestone Payments Plus Double-Digit Tiered Royalties

Innovus Pharma Signs Exclusive Marketing Sales And Distribution Agreement With Tramorgan Limited To Market And Distribute Sensum+(TM) In The United Kingdom

Innovus Pharma Signs Exclusive Marketing Sales And Distribution Agreement With Tramorgan Limited To Market And Distribute Sensum+(TM) In The United Kingdom

-Innovus Pharma Eligible to Receive Up to $44 Million in Sales Milestone Payments Based on Tramorgan's Cumulative Sales Plus 50% Royalties on Its Net Sales

Innovus Pharma Announces The Beginning Of Patient Enrollment In Its Post-Marketing EjectDelay(TM) Clinical Study In The Middle East

Innovus Pharma Announces The Beginning Of Patient Enrollment In Its Post-Marketing EjectDelay(TM) Clinical Study In The Middle East

Study Aimed at Quantifying the Delay in Ejaculation Time Achieved by the Use of the Product in Middle Eastern Men